Zomedica Q3 2025 revenue $8.1M (+16% YoY); net loss narrows to $6.1M

Zomedica Corp.

2025-Q3 EPS reported -$0.08 revenue$21,559,000

Revenue $8.1M, up 16% YoY; gross margin 67%; Diagnostics segment grew 51%.
Net loss $6.1M (down 9% YoY); adjusted EBITDA loss $3.9M.
Cash and securities $54.4M; operating expenses reduced $0.5M in Q3.
New Development Services segment generated $0.7M revenue in first quarter.
Record revenue for 19th straight quarter; new distribution agreements in UK, Netherlands, Canada.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.